Document text
Principal Investigator: R. PAUL JOHNSON
Organization: EMORY UNIVERSITY
Fiscal Year: 2024
Award: $74,999
Funding agency: NIH Office of the Director
PROJECT SUMMARY
With this R13 application, we request funding to support, in part, the costs for planning, publicizing, and hosting
the 39th, 40th, and 41st Annual Symposia on Nonhuman Primate Models for AIDS. For four decades, this
symposium has served as the premier scientific forum for the exchange of information, including new research
findings and scientific perspectives, among HIV/AIDS investigators whose research includes studies in
nonhuman primates (NHPs). Disseminating the latest research findings in NHP models of AIDS while also
facilitating discussion and exchange of information between basic scientists and clinicians remains a priority,
as do focusing on emerging technologies to accelerate translation of NHP studies into the clinic and engaging
a broader and more diverse group of researchers in HIV/AIDS research in NHP models. This meeting, the only
one of its kind in the world, convenes an international group of scientists whose research focuses on the study
of natural and experimental immunodeficiency virus infections in NHPs, as well as on the development of novel
therapeutics, prophylactic vaccines for HIV, and curative approaches. Emerging topics in related infectious
diseases (such as COVID-19 pathogenesis, vaccines and treatment) may also be included. The seven National
Primate Research Centers (NPRCs) host this meeting in rotation, and upcoming symposia hosts will be the
Yerkes (2022), California (2023), and Tulane (2024) NPRCs. We plan a hybrid format with most participants
attending in person and others joining online to access oral and poster sessions. The conference will begin on
day 1 with registration, a keynote address by a leading HIV/AIDS researcher, and an evening reception. The
following two and a half days will include scientific presentations from invited speakers and accepted oral
abstracts. Each symposium scientific committee will select session topics and speakers to highlight new and
cutting-edge technologies in their respective fields. Each session will open with a 30-minute talk by an invited
chair. Individuals whose abstracts are accepted for oral presentations will give the remaining session talks. A
poster session will occur on the evening of day 2, and there will be a banquet on the evening of day 3. As is
traditional for this symposium, the Journal of Medical Primatology will publish all poster and oral abstracts in a
special issue. In partnership with the HIV Vaccine Trials Network (HVTN), the NHP AIDS Symposium will also
host a pre-symposium meeting for early stage investigators (ESI). This meeting will be open to the attendees
of a linked ESI Conference the HVTN sponsors. ESI attendees and mentors will focus on grant writing,
budgeting, and networking, and will participate in a Q&A with NIH Program Officers. We believe bringing
together researchers from a variety of diverse backgrounds will generate future collaborations and scientific
advances. Knowledge shared and gained at upcoming Annual Nonhuman Primate Models for AIDS Symposia
will further the continued, effective use of NHP models to maintain long term control of HIV replication in the
absence of antiretroviral therapy and to design interventions to prevent or eradicate HIV infection.
Terms: <0-11 years old><2019-nCoV vaccine><21+ years old><AIDS><AIDS Vaccines><AIDS Virus><AIDS vaccine><AIDS/HIV><Acceleration><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Adult><Adult Human><Antibodies><Applications Grants><Budgets><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 pathogenesis><COVID-19 period><COVID-19 public health crisis><COVID-19 therapy><COVID-19 treatment><COVID-19 vaccine><COVID-19 years><COVID19 pathogenesis><CV-19><California><Child><Child Youth><Children (0-21)><Clinic><Clinical><Collaborations><Communicable Diseases><Coronavirus Infectious Disease 2019><Development><Disease><Disorder><Emergent Technologies><Emerging Technologies><Fees><Fostering><Funding><Future><Generations><Genomics><Grant><Grant Proposals><HIV><HIV Infections><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS><HIV/AIDS Vaccines><HTLV-III Infections><HTLV-III-LAV Infections><HVTN><Health><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Hybrids><Immunology><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Intervention><Intervention Strategies><Investigators><Journals><Knowledge><LAV-HTLV-III><Life><Link><Logistics><Lymphadenopathy-Associated Virus><Magazine><Medical><Mentors><Mission><Modeling><Modern Man><NIH><NIH Vaccine Research Center><National Institutes of Health><Oral><Oregon><Participant><Pathogenesis><Pennsylvania><Persons><Preventative vaccine><Prevention><Preventive vaccine><Primates><Primates Mammals><Prophylactic vaccine><Publishing><Research><Research Personnel><Researchers><Role><Rotation><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vaccine><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SIV><Scientific Advances and Accomplishments><Scientist><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Simian Immunodeficiency Viruses><Technology><Testing><Translations><Transmission><United States National Institutes of Health><Vaccines><Viral Diseases><Virus Diseases><Virus-HIV><Writing><adulthood><antiretroviral therapy><antiretroviral treatment><co-infection><coinfection><conference><convention><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccine><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 pathogenesis><coronavirus disease-19 vaccine><coronavirus infectious disease-19><cost><developmental><disability><experience><falls><global health><human immunodeficiency virus vaccine><hypoimmunity><immune deficiency><immunodeficiency><intervention design><interventional strategy><kids><meeting><meetings><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><neutralizing antibody><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-human primate><nonhuman primate><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><originality><posters><prevent><preventing><programs><response><scientific accomplishments><scientific advances><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><social role><summit><symposia><symposium><therapy design><translation><transmission process><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment design><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><viral infection><virus infection><virus-induced disease><youngster>